 4. Standard induction chemotherapy planned defined as: At least 4 cycles of platinum doublet chemotherapy for metastatic disease with or without bevacizumab, if the patient is known to be EGFR mutation positive, erlotinib, afatinib, or gefitinib for 3 months, or for patients with known EML4-ALK fusions, crizotinib for 3 months 